atakan/iStock by way of Getty Images
Altimmune (NASDAQ:ALT) shares superior on Tuesday after the corporate offered mid-stage outcomes for its obesity candidate, pemvidutide, at a European medical occasion on diabetes in Madrid, Spain.
Citing data from its Phase 2 MRI-based physique composition sub-study, MOMENTUM, the Gaithersburg, Maryland-based biotech mentioned that pemvidutide, a twin GLP-1/glucagon twin receptor agonist, preserved lean mass in chubby and overweight sufferers.
According to Altimmune (ALT), the lean loss ratio, which signifies the change in lean mass in comparison with complete mass, stood at 21.9% in 50 topics who acquired pemvidutide for 48 weeks.
Additionally, the drug was discovered to have a helpful impact on visceral adipose tissue, which is related to cardiovascular danger. According to the corporate, on the 2.4 mg dose, pemvidutide was linked to a 25.6% VAT discount in comparison with a 20.1% discount in subcutaneous adipose tissue.
The readout comes amid rising considerations over frequent unwanted effects related to fashionable weight reduction medicine comparable to semaglutide and tirzepatide marketed by Novo Nordisk (NVO) and Eli Lilly (LLY) for weight reduction.
“Given the breadth and diversity of the obesity patient population, there has been growing attention given to the quality of weight loss,” Altimmune’s (ALT) medical chief Scott Harris mentioned.
“Our data demonstrates pemvidutide’s class-leading lean mass preservation, superior to that reported traditionally with weight-reduction plan and train.”
Source: Seekingalpha